Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Caribou Biosciences, Inc. (CRBU) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
08/08/2023 8-K Quarterly results
Docs: "Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/14/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "CARIBOU BIOSCIENCES, INC. 19,230,769 Shares of Common Stock",
"10022-7650",
"Caribou Biosciences Announces Proposed Public Offering of Common Stock",
"Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering"
07/14/2023 8-K/A Quarterly results
07/13/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL",
"of the Private Securities Litigation Reform Act of 1995. These"
07/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FL1 40M 8 CR 1 DLBCL 40M 4 CR 4 DLBCL2 80M 1 CR 7 DLBCL2 80M 1 CR 8 PMBCL3 40M 2 CR 5 MCL 40M 2 CR 134 DLBCL 80M 2 CR 9 MZL 80M 4 PR 154 MCL 40M 4 CR 2 FL1 40M 2 CR 3 DLBCL 40M 2 CR 6 DLBCL 120M 2 CR 10 HGBL2 40M 1 PR 144 MCL 80M 2 PR 164 HGBL2 120M 1 PR 12 DLBCL 120M 2 SD 11 9 15"
07/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "SECURITIES PURCHASE AGREEMENT",
"VOTING AGREEMENT",
"Caribou Biosciences Announces $25 Million Equity Investment from Pfizer"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update"
04/04/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma"
03/29/2023 8-K Quarterly results
03/29/2023 8-K Quarterly results
03/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
12/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/29/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "-- RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial --"
11/21/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma"
11/08/2022 8-K Quarterly results
Docs: "Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update"
11/03/2022 8-K Quarterly results
10/18/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022"
09/22/2022 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
07/18/2022 8-K/A Quarterly results
07/15/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/25/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association 2022 Hybrid Congress --Abstract accepted for initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou’s lead allogeneic cell therapy for patients with r/r B-NHL --"
03/21/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update -- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for patients with r/r multiple myeloma -- -- Leadership team expanded with appointment of Syed Rizvi, M.D., as chief medical officer -- -- Cash, cash equivalents, and marketable securities of $413.5 million as of December 31, 2021 support advancement of wholly owned pipeline of allogeneic CAR-T and CAR-NK cell therapies --"
01/19/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "OFFICE/LABORATORY LEASE BETWEEN 7TH STREET PROPERTY III GENERAL PARTNERSHIP AND CARIBOU BIOSCIENCES, INC. 2895 Seventh Street Berkeley, California 00066513.5 Table of Contents Page ARTICLE 1 BASIC LEASE PROVISIONS 1 1.1 BASIC LEASE PROVISIONS 1 1.2 ENUMERATION OF EXHIBITS AND RIDER 3 1.3 DEFINITIONS 3 ARTICLE 2 PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING 10 2.1 LEASE OF PREMISES 10 2.2 TERM 10 2.3 FAILURE TO DELIVER POSSESSION 13 2.4 CONDITION OF PREMISES 13 2.5 PARKING 13 ARTICLE 3 RENT 14 ARTICLE 4 RENT ADJUSTMENTS AND PAYMENTS 14 4.1 RENT ADJUSTMENTS 14 4.2 STATEMENT OF LANDLORD 15 4.3 BOOKS AND RECORDS 16 4.4 TENANT OR LEASE SPECIFIC TAXES 17 ARTICLE 5 SECURITY 17 ARTICLE 6 SERVICES 18 6.1 LANDLORD'S GENERAL SERVICES 18 6.2 UTILITIES AND JANITORIAL SERVICES 19 6.3 ADDITIONA..."
01/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer Dr. Rizvi brings significant experience in oncology cell therapy development"
11/09/2021 8-K Quarterly results
Docs: "Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010 Expanded leadership with appointments of Ran Zheng and Dara Richardson-Heron, M.D., to board of directors and Ruhi Khan as chief business officer Ended third quarter with strong cash position of $435.3 million"
11/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy